In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novartis signs small-molecule deal with Infinity

Executive Summary

Novartis and Infinity Pharmaceuticals (small-molecule oncology therapeutics) will jointly design small molecules that Infinity will then synthesize with its chemical technology. Both companies have the right to use the resulting compound library in their separate drug discovery activities.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register